The Company Zydus Cadila Generics Aims to Achieve Sales Worth US$400 Million by 2006
Dublin (PRWEB) April 27, 2006
Research and Markets (http://www. researchandmarkets. com/reports/c36176 (http://www. researchandmarkets. com/reports/c36176)) has announced the addition of Zydus Cadila Generics Company Intelligence Report from Espicom Business Intelligence to their offering.
The generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the companys active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Cadila was founded in 1952, with its first API plant, at Ankleshwar, in Gujarat, being founded in 1970. By the early 1990s, Cadila claimed to be ranked third largest pharmaceutical company in India. The company was restructured in 1995, becoming the Zydus Cadila Group. Within this, Cadila Healthcare was established as the flagship company; Cadila Healthcare was subsequently launched as an IPO in February 2000.
During the course of fiscal year 2002/03, Zydus Cadila initiated the merger of four of its companies, German Remedies, Recon Healthcare, Zoom Properties and Zydus Pathline with Cadila Healthcare, the Zydus Group’s flagship company. The merger was approved in June 2003, and made effective since 1st April 2002.
The company aims to achieve sales worth US$400 million by 2006, and become a top ten global generic company with sales in excess of US$1 billion by 2010. It intends to do this by making forays into the US and EU and other markets - particularly Brazil and the Commonwealth of Independent States - worldwide. Zydus Cadila has two companies set up in the US - Zydus Healthcare (USA) and Zydus Pharmaceuticals (USA) - to sell APIs and generics. Zydus also entered the generics market in France by acquiring Alpharma’s subsidiary, which the company renamed Zydus France.
For more information visit http://www. researchandmarkets. com/reports/c36176 (http://www. researchandmarkets. com/reports/c36176)
Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 4100 980
# # #
